PGY2 Residency

PGY2 Pharmacy Residency in Thrombosis and Hemostasis Management

PGY2 Pharmacy Residency in Thrombosis and Hemostasis Management

Thrombosis and Hemostasis Management (THM) is the newest category of specialty residency training for pharmacists recognized by the American Society of Health-System Pharmacists (ASHP), the sole accrediting body for pharmacy residency programs in the United States. Created in 2022, this dynamic clinical specialty spans all aspects of the health care system, including ambulatory and acute care experiences, and provides focused training in emergency medicine, cardiology, critical care, hematology, and much more. Anticoagulation Forum is pleased to support the growth THM programs around the country as a key means of advancing safe and effective anticoagulant-related care and promoting Anticoagulation Stewardship.

Visit us at the ASHP MidYear Meeting

Visit the AC Forum and the PGY2 Residency Programs at the upcoming ASHP MidYear meeting!
December 8-12, 2024 in New Orleans
https://midyear.ashp.org/

Have questions? Are you interested in starting a PGY2 Residency at your site? Do you have or are you a PGY1 resident interested in the PGY2 Residency MATCH? Get all your questions answered!

2025 MATCH Day Information

ASHP Participating PGY2 Thrombosis and Hemostasis Management Programs

Learn More




ASHP MATCH Day Resources and the Road to Residency Guide

Learn More




ASHP MATCH Calendar

Learn More





Current THM Residency Sites (as of July 2024)

Prospective candidates are encouraged to explore the links to each site and any additional resources provided:


*Funded by Anticoagulation Forum’s TRAIN Grant

Let’s hear from the first-in-nation THM resident!

Kristi Schwietz, Brigham and Women’s Hospital

Inaugural PGY2 THM Residency Initiated at Brigham and Women’s Hospital

The Brigham & Women’s Hospital, Boston Massachusetts launched the nation's first PGY2 Residency in Thrombosis and Hemostasis Management in July 2022. This novel specialty residency program was formally approved by the ASHP Council on Credentialing (COC) in April 2022. The necessary framework on goals, objectives and structure have been finalized and were posted in PharmAcademic in Fall 2022 for programs interested in accessing this information.


Program Need

Anticoagulants are the leading class of medications associated with emergency department visits for adverse events. The rapid expansion of approved anticoagulants, indications for their use, associated reversal strategies, and increasing overall prescribing makes safe and effective patient care increasingly complex and costly. Pharmacists play pivotal roles in thrombosis and hemostasis management and in the implementation and operation of successful multidisciplinary anticoagulation and hemostasis stewardship programs. Yet currently available residency programs do not fully prepare pharmacists for work in this dynamic and expanding field. This new ASHP-accredited PGY2 Residency in Thrombosis and Hemostasis Management will prepare pharmacists to practice in this rapidly evolving discipline and to cement the role of pharmacists in multidisciplinary anticoagulation stewardship programs.





About the Anticoagulation Forum

The Anticoagulation Forum (AC Forum) is a nonprofit organization dedicated to improving the quality of patient care by educating healthcare professionals and advocating for clinical best practices in the field of antithrombotic medications. Founded in 1991, the AC Forum is the largest organization of anticoagulation management specialists, made up of 14,000 physicians, pharmacists, and nurses representing over 3,000 anticoagulation practices and supporting over 1 million patients annually.

This program is sponsored in part by AstraZeneca, the BMS/Pfizer Alliance, and Janssen Pharmaceuticals, Inc.